A biotech startup called Altimmunce based in Maryland, USA, is in a bid to develop a nasal spray to fight COVID-19.
The startup company started their trial of the intranasal vaccine – AdCOVID – on a group of 180 individuals, ranging from 18 to 55 years of age and studied the effectiveness of vaccine, along with the kind of side-effects it prompts and the number of antibodies and T-cells it produces.
In an interview, Dr. Buddy Creech, Director of Vanderbilt University vaccine-research program and someone who worked with Altimmune, said, “Delivering vaccines to the sight of first exposure is an advantage.” “Typically, you don’t get COVID-19 in the deltoid muscle of your arm – you get it in your nose, eyes, and throat. So it makes sense we’d want to at least consider a vaccine that can generate some immunity in mucosal orifices, ” he adds.
The nasal vaccine looks forward to creating a separate line of defense in the mucosal membrane and prompts the immune system to produce antibodies that can block the infection.